Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

31.27
-0.3450-1.09%
Volume:2.02M
Turnover:63.33M
Market Cap:36.42B
PE:25.84
High:31.75
Open:31.66
Low:31.21
Close:31.61
52wk High:37.35
52wk Low:13.04
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.82
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:4.60
PE(LYR):25.84

Loading ...

US appeals court revives Teva lawsuit against Eli Lilly over migraine drug

Reuters
·
Yesterday

Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)?

Simply Wall St.
·
Apr 13

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Teva Pharmaceutical Industries to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Apr 09

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.
·
Apr 04

Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential

Simply Wall St.
·
Mar 31

Teva call volume above normal and directionally bullish

TIPRANKS
·
Mar 31

Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 30

How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases

Simply Wall St.
·
Mar 26

Scotiabank Remains a Buy on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 25

Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock

TIPRANKS
·
Mar 21

Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 20

Top Teva Executive Makes Major Stock Move That Investors Can’t Ignore

TIPRANKS
·
Mar 20

A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Branded Drugs Pass $1b Quarterly Revenue

Simply Wall St.
·
Mar 17

J.P. Morgan Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Mar 05

Teva Pharmaceuticals Price Target Raised to $41.00/Share From $40.00 by Piper Sandler

Dow Jones
·
Mar 04

Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug

MT Newswires Live
·
Mar 04

BRIEF-Teva Unveils Spring 2026 Collection “For Playground Earth” Evolves For Wherever Adventure Leads

Reuters
·
Mar 03

Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential

Simply Wall St.
·
Mar 03